Рет қаралды 3,087
As we await a decision from the FDA on the New Drug Application for Omaveloxolone in FA, we reflect on the many FA community contributions that brought us to this point. This animated video shares a summary of how a community helps advance drug development. Thank you to the research community, clinical research participants, and FARA supporters for the gift of your expertise, time, voice, and resources.
FARA's Mission is to marshal and focus the resources and relationships needed to cure Friedreich's Ataxia (FA) by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases.
Friedreich’s Ataxia is a debilitating, life-shortening, degenerative neuro-muscular disorder. About one in 50,000 people in the United States have Friedreich's Ataxia.
Subscribe to FARA's KZbin channel / fara1998
Follow FARA on Facebook / curefa
Follow FARA on Instagram / curefa_org